CONTRATOS ART. 83
Contrato
A PHASE IV OPEN-LABEL CLINICAL TRIAL TO EVALUATE THE EFFICACY OF IKERVIS ON CLINICAL PARAMETERS AND MOLECULAR/CELLULAR BIOMARKERS IN DRY PATIENTS WITH SEVERE DERATITIS WHO HAVE NOT IMPROVED DESPITE REGULAR USE OF TEAR SUBSTITUTES BEFORE AND AFTER EXPOSURE TO AN ADVERSE CONTROLLED ENVIRONMENT.
Financiador:
SANTEN SA
Europeo
date_range
Duración del 29 de abril de 2019 al 28 de abril de 2021
(24 meses)
euro
60.677,20 EUR
De ámbito Europeo.